Search academic texts

Information × Registration Number 0218U002566, 0115U004199 , R & D reports Title Development of novel preventive technologies in treatment of acute rheumatic diseases popup.stage_title Head Kit Yuriy Yaroslavovych, Registration Date 13-04-2018 Organization Institute of cell biology, National Academy of Sciences of Ukraine popup.description2 In the study of TAA-soluble fraction of blood serum of patients with multiple sclerosis by high-performance liquid chromatography with the following mass spectrometric analysis of chromatographic fractions, for the first time, we had a short form (46-48 kDa) of unconventional myosin 1C (48kDa Myo 1C) and peptides of 300-500 Da composed from monomeric and monomeric peptide forms with the Ser-Pro-Cys (proersercin) sequence. It was found that serum myosin 1C has cytostatic activity and proerserts with cytotoxic activity in tumorous pseudo normal and normal (leukocyte) cells in vitro. We examined the relationship between the content of 48kDa Myo 1C in serum of patients with multiple sclerosis (MS) and an individual feature of the course of this disease. The study was attended by 61 patients in the MS and 20 clinically healthy individuals aged 19 to 57 years. In the group of patients with PC with a high level of 48 kD Myo1c, the average age of the patients surveyed at the onset of the disease was the lowest, but the probable statistical relationship between the concentration of 48 kD Myo1c in the blood serum of patients and the age of the debut PC was not revealed. At the debut of the RS in the form of a disturbance in visual acuity in the blood serum of patients, the average level of Myo1c was 48 kDa, and at the debut of the oculomotor disorder, it was more likely that the level was low, indicating a less favorable course of the disease. The level of 48 kD Myo1c in the blood serum of the examined individuals is statistically significantly independent of the activity of the disease at the time of examination and blood collection, and therefore, the use of this biomarker is possible not only in case of exacerbation of the disease, but also in remission Key words: autoimmune diseases, blood serum, proteins, peptides, cytotoxicity, markers of multiple sclerosis. Product Description popup.authors Старикович Марина Олексіївна popup.nrat_date 2020-04-02 Close